报价延迟最少15分钟:2026/03/29 12:56 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.74 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.11/0.25
|
|
企业价值
931.46M
|
| 资产负债 |
|
每股账面净值
-1.18
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
403.14M
|
|
每股收益
0.43
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet. |
